Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Will LCZ696 still launch after Alzheimer's WSJ article?
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 5363526"]You are correct on readmission and bonus structure, however, here is the question. Which will provide greater return- an overpriced agent with no real world experience, or an effective compliance program. I contend that investing in compliance is a much better choice. You will produce much greater results improving compliance to the traditional regimen than just adding a new agent.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 5363526"]You are correct on readmission and bonus structure, however, here is the question. Which will provide greater return- an overpriced agent with no real world experience, or an effective compliance program. I contend that investing in compliance is a much better choice. You will produce much greater results improving compliance to the traditional regimen than just adding a new agent.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Will LCZ696 still launch after Alzheimer's WSJ article?
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Will LCZ696 still launch after Alzheimer's WSJ article?
>